MELAS Syndrome
3
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Human BioSciencesWV - Martinsburg
2 programs1
1
Fluzone®Phase 41 trial
DichloroacetatePhase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Human BioSciencesFluzone®
Santhera PharmaceuticalsIdebenone
Human BioSciencesDichloroacetate
Clinical Trials (3)
Total enrollment: 84 patients across 3 trials
Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS)
Start: Sep 2010Est. completion: Mar 201222 patients
Phase 4Completed
Study of Idebenone in the Treatment of Mitochondrial Encephalopathy Lactic Acidosis & Stroke-like Episodes
Start: May 2009Est. completion: Jul 201227 patients
Phase 2Completed
Evaluating the Effectiveness of a Dichloroacetate in MELAS Syndrome
Start: Mar 200035 patients
Phase 2Unknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.